Able Sciences
RNA-based Off the Shelf Immune Cells for Cell Therapies
Operating in therapeutics based in United States, Able Sciences was founded in 2023.
Profile
Able Sciences, Inc. (Able) is deploying a leading-edge RNA technology platform to develop highly differentiated off-the-shelf, cost-effective cell therapies leading with allogeneic NK cells to cure Solid Cancers and Autoimmune Disorders.
The company sits in the therapeutics segment, where it competes on its core product or service.
United States is where the company is located.
Directory data places it at the SOSV portfolio company stage.
Its team size is recorded as 2-10 employees.
It has disclosed roughly $525K in funding.
| Sector | Therapeutics |
|---|---|
| Country | United States |
| Founded | 2023 |
| Employees | 2-10 |
| Stage | SOSV portfolio company |
| Total funding | $525,000 |
Website: ablesciences.com
Sign in to view the contact information we hold for Able Sciences.
Create a free account
Create a free account